Utilizing labour and delivery units for remdesivir infusion for high-risk pregnant and postpartum patients with mild-to-moderate disease during a COVID-19 surge

J Hosp Infect. 2022 Nov:129:38-40. doi: 10.1016/j.jhin.2022.08.001. Epub 2022 Aug 6.

Authors

R Herz-Roiphe¹, A Y Kim², A J Kaimal³, I T Goldfarb³

Affiliations

¹ Harvard Medical School, Boston, MA, USA. Electronic address: rachel_herz-roiphe@hms.harvard.edu.
² Harvard Medical School, Boston, MA, USA; Department of Infectious Disease, Massachusetts General Hospital, Boston, MA, USA.
³ Harvard Medical School, Boston, MA, USA; Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, USA.

No abstract available

MeSH terms

Adenosine Monophosphate / therapeutic use
COVID-19 Drug Treatment
COVID-19*
Female
Humans
Postpartum Period
Pregnancy
Pregnancy Complications, Infectious* / drug therapy

Substances

remdesivir
Adenosine Monophosphate